PHARMACOKINETICS AND SAFETY OF ELAFIBRANOR IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION

被引：0
|
作者：
Noel, Benoit [1 ]
Vargas, Dawn [2 ]
Georges-Coty, Anne [1 ]
Roudot, Alice [1 ]
Roux, Olivier [3 ]
Magrez, David [1 ]
Wyatt, David [4 ]
Birman, Pascal [1 ]
Addy, Carol [1 ,5 ]
机构：
[1] Genfit SA, Loos, France
[2] Genfit CORP, Loos, France
[3] It&m Stats, Neuilly Sur Seine, France
[4] Syneos Hlth, Morrisville, NC USA
[5] Genfit SA, Clin Dev, Loos, France
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1287
引用
收藏
页码：772A / 773A
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
    Borin, Marie T.
    Lo, Arthur
    Barnes, Chris N.
    Pendyala, Srikanth
    Bourdet, David L.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 2305 - 2318
  • [2] Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects
    Shah, Jaymin
    Pozo, Katherine
    Scott, Deborah
    Lin, WeiQi
    JOURNAL OF HEPATOLOGY, 2021, 75 : S613 - S613
  • [3] Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
    Miyazawa, Y
    Blum, RA
    Schentag, JJ
    Kamimura, H
    Matsushima, H
    Swarz, H
    Ito, Y
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (09): : 603 - 621
  • [4] The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function
    Everson, G
    Lasseter, KC
    Anderson, KE
    Bauer, LA
    Carithens, RL
    Wilner, KD
    Johnson, A
    Anziano, RJ
    Smolarek, TA
    Turncliff, RZ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 21S - 26S
  • [5] EVALUATION OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF A SINGLE DOSE OF ALDAFERMIN IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION
    Li, Yan
    Chan, Ming Liang
    Harr, Mihoko
    Rondon, Juan
    Marbury, Thomas C.
    Lawitz, Eric J.
    Ling, Lei
    Willett, Michael S.
    HEPATOLOGY, 2022, 76 : S663 - S664
  • [6] Pharmacokinetics of nilotinib in subjects with normal or impaired hepatic function
    Holland, Jaymes
    Tanaka, Chiaki
    Zhou, Wei
    Sethuraman, Venkat
    Heuman, Douglas M.
    Schran, Horst
    BLOOD, 2007, 110 (11) : 702A - 702A
  • [7] Asunaprevir Pharmacokinetics and Safety in Subjects With Impaired Renal Function
    Garimella, Tushar
    He, Bing
    Luo, Wen-Lin
    Colston, Elizabeth
    Zhu, Kurt
    Kandoussi, Hamza
    Marbury, Thomas C.
    Alcorn, Harry W.
    Smith, William B.
    Eley, Timothy
    HEPATOLOGY, 2013, 58 : 430A - 430A
  • [8] Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
    Berg, Jolene K.
    Tzanis, Evan
    Garrity-Ryan, Lynne
    Bai, Stephen
    Chitra, Surya
    Manley, Amy
    Villano, Stephen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)
  • [9] Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function
    Khosravan, Reza
    Toh, Melvin
    Garrett, May
    La Fargue, JoAnn
    Ni, Grace
    Marbury, Thomas C.
    Swan, Suzanne K.
    Lunde, Norman M.
    Bello, Carlo L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04): : 472 - 481
  • [10] Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
    Kunz, Christina
    Luedtke, Doreen
    Unseld, Anna
    Hamilton, Alan
    Halabi, Atef
    Wein, Martina
    Formella, Stephan
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 585 - 595
12345